Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo

Dendritic cells (DCs) have been well characterized for their ability to initiate cell-mediated immune responses by stimulating naive T cells. However, the use of DCs to stimulate antigen-activated T cells in vivo has not been investigated. In this study, we determined whether DC vaccination could improve the efficacy of activated, adoptively transferred T cells to induce an enhanced antitumor immune response. Mice bearing B16 melanoma tumors expressing the gp100 tumor antigen were treated with cultured, activated T cells transgenic for a T-cell receptor specifically recognizing gp100, with or without concurrent peptide-pulsed DC vaccination. In this model, antigen-specific DC vaccination induced cytokine production, enhanced proliferation, and increased tumor infiltration of adoptively transferred T cells. Furthermore, the combination of DC vaccination and adoptive T-cell transfer led to a more robust antitumor response than the use of each treatment individually. Collectively, these findings illuminate a new potential application for DCs in the in vivo stimulation of adoptively transferred T cells and may be a useful approach for the immunotherapy of cancer.

[1]  T. Waldmann,et al.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Bishop,et al.  Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. , 2004, Seminars in oncology.

[3]  J. F. Carpenter,et al.  Studies on the mechanism of action of dantrolene sodium , 1972, Naunyn-Schmiedeberg's Archives of Pharmacology.

[4]  V. Cerundolo,et al.  Dendritic cells: a journey from laboratory to clinic , 2004, Nature Immunology.

[5]  V. Engelhard,et al.  Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control , 2003, The Journal of experimental medicine.

[6]  Steven A. Rosenberg,et al.  Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.

[7]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[8]  P. Coulie,et al.  T-cell responses of vaccinated cancer patients. , 2003, Current opinion in immunology.

[9]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Yewdell,et al.  Viral interference with antigen presentation , 2002, Nature Immunology.

[11]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[12]  T. Glant,et al.  Trafficking of CD44‐deficient murine lymphocytes under normal and inflammatory conditions , 2002, European journal of immunology.

[13]  P. Hwu,et al.  Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. , 2002, The Journal of clinical investigation.

[14]  M. Cheever,et al.  Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  E. Padovan,et al.  Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. , 2002, Human gene therapy.

[16]  M. Udey,et al.  Dendritic Cells Transduced with Protein Antigens Induce Cytotoxic Lymphocytes and Elicit Antitumor Immunity1 , 2002, The Journal of Immunology.

[17]  F. Marincola,et al.  Immunotherapy against antigenic tumors: a game with a lot of players , 2002, Cellular and Molecular Life Sciences CMLS.

[18]  J. Becker,et al.  Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progression , 2001, International journal of cancer.

[19]  I. Verma,et al.  Gene therapy: promises and problems. , 2001, Annual review of genomics and human genetics.

[20]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.

[21]  F. Marincola,et al.  Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma , 2001, Journal of immunotherapy.

[22]  Rolf M. Zinkernagel,et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.

[23]  L. Lefrançois,et al.  Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue , 2001, Science.

[24]  O. Bathe,et al.  Reversal of CD8+ T Cell Ignorance and Induction of Anti-Tumor Immunity by Peptide-Pulsed APC1 , 2000, The Journal of Immunology.

[25]  A. Enk,et al.  Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells1 , 2000, The Journal of Immunology.

[26]  R. Tisch,et al.  T Cell Activity After Dendritic Cell Vaccination Is Dependent on Both the Type of Antigen and the Mode of Delivery1 , 2000, The Journal of Immunology.

[27]  R. Steinman,et al.  Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. , 2000, The Journal of clinical investigation.

[28]  M. Dailey,et al.  Traffic of L-selectin-negative T cells to sites of inflammation. , 2000, European journal of immunology.

[29]  A. Cerwenka,et al.  Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. , 1999, Journal of immunology.

[30]  L. Lefrançois,et al.  Induction and visualization of mucosal memory CD8 T cells following systemic virus infection. , 1999, Journal of immunology.

[31]  T. Olencki,et al.  T-cell adoptive immunotherapy of metastatic renal cell carcinoma. , 1999, Urology.

[32]  R. Steinman,et al.  Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. , 1999, Human immunology.

[33]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[34]  J. Mulé,et al.  Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Siegel,et al.  Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. , 1999, Annual review of immunology.

[36]  H. Pircher,et al.  Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. , 1998, Journal of immunology.

[37]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[38]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[39]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[40]  S. Rosenberg,et al.  Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. , 1997, Journal of the National Cancer Institute.

[41]  H. Degrendele,et al.  Requirement for CD44 in activated T cell extravasation into an inflammatory site. , 1997, Science.

[42]  S. Rosenberg,et al.  Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases , 1997, The Journal of experimental medicine.

[43]  J. Krauss,et al.  Treatment of subcutaneous tumor with adoptively transferred T cells. , 1997, Cellular immunology.

[44]  J. Karbach,et al.  Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens , 1996, International journal of cancer.

[45]  W. Storkus,et al.  B 7 Cost imulat ion , and T Helper Cell 1-associated Cytokines , 2003 .

[46]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[47]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[48]  R. Cameron,et al.  Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action , 1990, The Journal of experimental medicine.

[49]  S M Larson,et al.  Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[51]  K. Hellström,et al.  Cytotoxicity of human rosette‐forming blood lymphocytes on cultivated human tumor cells , 1974, International journal of cancer.